Completed PHASE2 INTERVENTIONAL 1-arm NCT00082810

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Estrogen Receptor-positive Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer

Interventions fulvestrant tipifarnib

Updated 8 times since 2017 Last updated: Oct 4, 2018 Started: Mar 31, 2004 Primary completion: Jul 31, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Estrogen Receptor-positive Breast Cancer and Recurrent Breast Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• The Bronx, United States